Self-expanding metal stents (SEMS) provide superior outcomes compared to plastic stents for pancreatic cancer patients undergoing neoadjuvant therapy

Journal of Gastrointestinal Oncology

Volumn 3, Issue 4, 2012, Pages 309-313

  Adams, Megan A ^a   Anderson, Michelle A ^a   Myles, James D ^b   Khalatbari, Shokoufeh ^b   Scheiman, James M ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Bile duct stents; Chemotherapy; Jaundice; Pancreatic cancer

Indexed keywords

GEMCITABINE;

ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; CANCER PATIENT; CHOLESTASIS; COHORT ANALYSIS; COMPLICATION; CONTROLLED STUDY; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; METAL STENT; OUTCOME ASSESSMENT; PANCREAS CANCER; PLASTIC STENT; RETROSPECTIVE STUDY; SELF EXPANDING STENT; STENT RELATED COMPLICATION; TUMOR VOLUME;

EID: 84995752971     PISSN: 20786891     EISSN: 2219679X     Source Type: Journal    
DOI: 10.3978/j.issn.2078-6891.2011.050.pdf     Document Type: Article

References (14)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Evans DB, Varadhachary GR, Crane CH, et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008;26:3496-502.
3. Gillen S, Schuster T, Meyer Zum Büschenfelde C, et al. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 2010;7:e1000267.
4. Artinyan A, Anaya DA, McKenzie S, et al. Neoadjuvant therapy is associated with improved survival in resectable pancreatic adenocarcinoma. Cancer 2011;117:2044-9.
5. Sharma C, Eltawil KM, Renfrew PD, et al. Advances in diagnosis, treatment and palliation of pancreatic carcinoma: 1990-2010. World J Gastroenterol 2011;17:867-97.
6. Weston BR, Ross WA, Wolff RA, et al. Rate of bilirubin regression after stenting in malignant biliary obstruction for the initiation of chemotherapy: how soon should we repeat endoscopic retrograde cholangiopancreatography? Cancer 2008;112:2417-23.
7. Wasan SM, Ross WA, Staerkel GA, et al. Use of expandable metallic biliary stents in resectable pancreatic cancer. Am J Gastroenterol 2005;100:2056-61.
8. Lawrence C, Howell DA, Conklin DE, et al. Delayed pancreaticoduodenectomy for cancer patients with prior ERCP-placed, nonforeshortening, self-expanding metal stents: a positive outcome. Gastrointest Endosc 2006;63:804-7.
9. Mullen JT, Lee JH, Gomez HF, et al. Pancreaticoduodenectomy after placement of endobiliary metal stents. J Gastrointest Surg 2005;9:1094-104; discussion 1104-5.
10. Decker C, Christein JD, Phadnis MA, et al. Biliary metal stents are superior to plastic stents for preoperative biliary decompression in pancreatic cancer. Surg Endosc 2011;25:2364-7.
11. Boulay BR, Gardner TB, Gordon SR. Occlusion rate and complications of plastic biliary stent placement in patients undergoing neoadjuvant chemoradiotherapy for pancreatic cancer with malignant biliary obstruction. J Clin Gastroenterol 2010;44:452-5.
12. Lofts FJ, Evans TR, Mansi JL, et al. Bile duct stents: is there an increased rate of complications in patients receiving chemotherapy? Eur J Cancer 1997;33:209-13.
13. Nakai Y, Isayama H, Kawabe T, et al. Efficacy and safety of metallic stents in patients with unresectable pancreatic cancer receiving gemcitabine. Pancreas 2008;37:405-10.
14. Moss AC, Morris E, Leyden J, et al. Do the benefits of metal stents justify the costs? A systematic review and meta-analysis of trials comparing endoscopic stents for malignant biliary obstruction. Eur J Gastroenterol Hepatol 2007;19:1119-24.